Cronus Pharma Announces the Launch of Florfinasone™ Otic for the Treatment of Otitis Externa in Dogs

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Cronus Pharma Announces the Launch of Florfinasone™ Otic for the Treatment of Otitis Externa in DogsAuthor of the article:Business Wire Business WireEAST BRUNSWICK, N.J. — Cronus Pharma LLC, a fully integrated animal health company, today announced the launch of Florfinasone Otic (florfenicol, terbinafine, mometasone furoate), an FDA-approved product indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountThis advertisement has not loaded yet, but your article continues below.Florfinasone Otic is a fixed-combination therapy that provides antibacterial, antifungal, and anti-inflammatory activity in a convenient single-use formulation. The product contains 16.6 mg/mL florfenicol, 14.8 mg/mL terbinafine (equivalent to 16.6 mg/mL terbinafine hydrochloride), and 2.2 mg/mL mometasone furoate. Proper patient selection is important when veterinarians consider the benefits and risks of using Florfinasone Otic. The integrity of the tympanic membrane should be confirmed before administering the product. Florfinasone Otic is not for use in cats.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try again“At Cronus Pharma, we are committed to delivering high-quality, cost-effective solutions that improve animal health outcomes and support veterinarians in clinical practice,” said Janel Fisher, Vice President of Sales at Cronus Pharma. “The launch of Florfinasone Otic expands our portfolio with an effective treatment option designed to address susceptible bacterial, fungal, and inflammatory components commonly associated with canine otitis externa.”Florfinasone Otic combines three active ingredients with complementary mechanisms of action:Florfenicol: A bacteriostatic antibiotic that acts by inhibiting protein synthesis.Terbinafine: An antifungal agent that selectively inhibits the early synthesis of ergosterol.Mometasone Furoate: A glucocorticosteroid with anti-inflammatory activity.This product is approved by the U.S. Food and Drug Administration under ANADA #200-848 and is currently available in cartons of ten single-use dropperettes, with each dropperette containing 1mL dose for convenient administration.Accessible to Veterinarians Nationwide Cronus Pharma’s Florfinasone OTIC is available through national and regional distributors, making it convenient for veterinarians to access this important medication for canine otitis. Full product information is available from your veterinarian and should be reviewed prior to use. Our focus on quality and accessibility ensures that veterinarians and pet owners can trust our products.Based in East Brunswick, New Jersey, Cronus Pharma is a privately held veterinary generic pharmaceutical company dedicated to advancing animal health. With integrated research, development, manufacturing, and marketing, we deliver innovative and cost-effective solutions for animals. Our passionate team of scientists is actively developing new products, with a robust pipeline awaiting FDA approval. Cronus Pharma is committed to supporting veterinarians and pet owners with high-quality, accessible solutions.Learn more about our mission to enhance animal health at www.cronuspharmausa.com.View source version on businesswire.com: Phone: 844-2-CRONUS (844-227-6687)This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.